

1/20





FIG. 1

2/20



* pANCA2(-) = $\emptyset$ OR + 1 pANCA (NOT DETECTED OR WEAK)

FIG. 2

3/20




FIG. 3

4/20




FIG. 4




FIG. 5

6/20




FIG. 6






FIG. 7

8/20

A**B****FIG. 8**





FIG. 9

**FIG. 10**

11/20




FIG. 11

12/20




FIG. 12

13/20




FIG. 13




FIG. 14




FIG. 15

IBD sgi cohort Serological markers

		non-IBD (n=620)	CD (n=572)	UC (n=328)
Serological Markers	ASCAA	9.83%	52.62%	7.93%
	ASCAG	11.77%	48.43%	9.76%
	ANCA	6.29%	24.13%	62.80%
	pANCA	3.23%	20.98%	61.59%
	OmpC	15.16%	37.41%	21.95%
	CBir1	15.97%	39.51%	17.38%
	Fla2	11.94%	44.41%	15.85%
	FlaX	11.61%	44.41%	16.46%




FIG. 16

17/20

IBD sgi cohort Inflammatory markers

		non-IBD (n=620)	CD (n=572)	UC (n=328)
Inflammatory markers	VEGF	18.23%	30.59%	28.05%
	CRP	17.26%	33.92%	24.09%
	SAA	13.06%	37.59%	25.61%
	ICAM	18.55%	30.42%	28.05%
	VCAM	19.03%	27.97%	31.40%






FIG. 17

18/20

More IBD than Non-IBD patients are positive for two or more genetic markers

# positive genetic markers	% Non-IBD patients	% IBD patients
0	31.8%	27.1%
1	45.6%	42.0%
2	18.2%	23.7%
3	4.2%	6.9%
4	0.2%	0.3%


# positive genetic markers	# Non-IBD patients	# IBD patients
Fewer than 2	480 (77%)	622 (69%)
2 or more	140 (23%)	278 (31%)

This trend is statistically significant (Chi-square association test, $p=0.0004$).

FIG. 18

19/20

IBD sgi Performs Better than IBD Serology 7 in Differentiating CD vs. UC



In a head-to-head comparison, IBD sgi demonstrated improved overall performance over IBD Serology 7 in differentiating CD vs. UC

	Absolute Improvement	Relative Improvement
CD / UC (AUC)	15%	19%

FIG. 19

20/20

Overall Diagnostic Performance

IBD sgi vs. IBD Serology 7

In a head-to-head comparison of diagnostic performance, IBD sgi demonstrated absolute and relative improvements over IBD Serology 7

n=373

	IBD sgi	IBD Serology 7	Absolute Improvement	Relative Improvement
IBD vs. Non-IBD (AUC)	0.87	0.80	7%	9%
CD / UC (AUC)	0.93	0.78	15%	19%

IBD vs nonIBD

	AUC	95%CI
sgi	0.87	0.8442 – 0.9070
Ser7	0.80	0.7682 – 0.8507

p=0.0001

CD vs UC

	AUC	95%CI
sgi	0.93	0.8585 – 0.9354
Ser7	0.78	0.7144 – 0.8403

p<0.0001

FIG. 20